The goals of the Virology Core are to enhance the research capacity of the UNC CFAR research community by providing access to state-of-the-art tools for diagnosis and monitoring HIV+ patients in clinical trials, and providing leadership to promote HIV/AIDS research in this area through collaboration, training, and mentoring.
The specific aims are to 1) provide quality viral assays and services, 2) provide training and mentorship to the domestic and international CFAR community and build capacity at international sites, 3) provide leadership through activities locally, nationally, and internationally, 4) support NIH networks and CFAR-CFAR collaborations by participating in CHAVI, HPTN, IMPAACT, and ACTG, 5) support new CFAR initiatives through collaborations with UNC CFAR members, and 6) engage in evaluation and strategic planning, using input from user surveys, an Internal Advisory Board, and the CFAR External Advisory Board. Through these activities, the Virology Core will continue to provide key infrastructure support for the HIV/AIDS research activity of the CFAR membership. These activities will have a significant impact on the future of the epidemic by providing HIV, HCV, and HPV viral assays, including ultra-low copy number and POC assays, training and mentoring new US and international scientists, and providing leadership locally, nationally, and globally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI050410-17
Application #
8708739
Study Section
Special Emphasis Panel (ZAI1-ELB-A)
Project Start
2014-08-01
Project End
2016-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
17
Fiscal Year
2014
Total Cost
$224,485
Indirect Cost
$72,590
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Edwards, Jessie K; Cole, Stephen R; Hall, H Irene et al. (2018) Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. AIDS 32:261-266
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Ford, Catherine; Chibwesha, Carla J; Winston, Jennifer et al. (2018) Women's decision-making and uptake of services to prevent mother-to-child HIV transmission in Zambia. AIDS Care 30:426-434
Tang, Weiming; Mao, Jessica; Liu, Chuncheng et al. (2018) Reimagining Health Communication: A Non-Inferiority Randomized Controlled Trial of Crowdsourced intervention in China. Sex Transm Dis :
Evon, D M; Amador, J; Stewart, P et al. (2018) Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther 47:1001-1011
Weber, Michael D; Andrews, Elizabeth; Prince, Heather A et al. (2018) Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women. Antivir Ther 23:495-504
Scheidell, Joy D; Quinn, Kelly; McGorray, Susan P et al. (2018) Childhood traumatic experiences and the association with marijuana and cocaine use in adolescence through adulthood. Addiction 113:44-56
Garrido, Carolina; Abad-Fernandez, Maria; Tuyishime, Marina et al. (2018) Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. J Virol 92:
Davy-Mendez, Thibaut; Eron, Joseph J; Brunet, Laurence et al. (2018) New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations. AIDS 32:2593-2603

Showing the most recent 10 out of 1688 publications